Core Viewpoint - The company, Harbin Sanlian (哈三联), is facing significant financial challenges, with an expected net loss of 315 million to 375 million yuan for the fiscal year 2025, marking its first annual loss since its listing in 2017 [1][2]. Financial Performance - The projected net loss for 2025 represents a year-on-year decline of 636.85% to 739.11% compared to the previous year, with a basic earnings per share expected to be between -1.19 yuan and -1 yuan [2]. - The company's revenue for 2025 is anticipated to be 790 million yuan, a decrease of 30% or 343 million yuan from the previous year [3]. Causes of Decline - The decline in performance is attributed to several factors, including a drop in sales prices due to national drug procurement policies and increased competition in the market [3]. - The company has reported a significant increase in operating costs and expenses, with sales expenses expected to rise by over 23.5 million yuan, primarily due to investments in the health sector [3]. - A substantial credit impairment loss of 24.626 million yuan has been recognized, primarily related to two counterparties [4]. Business Transition - The traditional pharmaceutical business of the company is under pressure, and its transition into animal health and wellness sectors has not yet yielded effective financial support [5]. - The pharmaceutical segment remains the core business, contributing over 86% of total revenue, but has seen a continuous decline in revenue and gross margin [6][7]. Market Position and Strategy - The company has made efforts to diversify into animal health and wellness, but these segments currently contribute only a small fraction (approximately 3.65%) of total revenue [7]. - Harbin Sanlian has participated in industry exhibitions to promote its cosmetic and medical products, indicating a strategic shift towards beauty and health markets [7]. Shareholding and Investments - As of the third quarter of 2025, the company still holds a 4.5% stake in Fulejia (敷尔佳), which is currently the only profitable investment among its subsidiaries [8].

Core Viewpoint - Harbin Sanlian (哈三联) has faced regulatory penalties for failing to disclose external financial assistance as required, leading to warnings issued by the Heilongjiang Securities Regulatory Bureau against the company and its executives [1] Financial Performance - In 2024, Harbin Sanlian reported a revenue of 1.132 billion yuan, a decrease of 4.58% year-on-year, and a net profit of 58.68 million yuan, down 20.35% year-on-year [2] - The company's net profit decline was attributed to the impact of centralized drug procurement policies, increased competition, and rising operating costs, while the non-recurring net profit increased by 73.85% to 53.23 million yuan [2] - The pharmaceutical segment generated 989 million yuan in revenue, a decline of 13.48%, with a gross margin of 55.34%, down 6.05% year-on-year [3] Securities Investment - Harbin Sanlian recorded a fair value loss of 14.63 million yuan from securities investments in 2024, primarily from holdings in the Hong Kong-listed company, Sihuan Pharmaceutical [3] - The company also reported a fair value change loss of 502.73 thousand yuan, a significant decrease of 236.44% year-on-year [4] Recent Developments - The company has been involved in financial transactions with Harbin Taishengchang Packaging and Printing Co., Ltd. and Zhongfu Pharmaceutical Co., Ltd., totaling 22.5 million yuan and 22 million yuan respectively, which were not fulfilled as per agreements [1]